Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements?
The EMERALD trial was an open label phase 3 trial evaluating elacestrant, the first oral selective estrogen receptor degrader (SERD), as compared to “standard of care”, in ER+/HER2- (hormone receptor positive, no HER2 overexpression) advanced or metastatic breast cancer.The EMERALD trial restricted...
Guardado en:
Autores principales: | Timothée Olivier, Vinay Prasad |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4107528f9cd04a91a32dd75aa46d91c5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Metastatic breast cancer: Endocrine therapy landscape reshaped
por: Mohamad Adham Salkeni, et al.
Publicado: (2017) -
Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer
por: Cenzhu Wang, et al.
Publicado: (2021) -
Metastatic Breast Cancer to the Urinary Bladder in the Caribbean
por: Saara Mohammed, et al.
Publicado: (2021) -
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Yizhao Xie, et al.
Publicado: (2021) -
Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab M, et al.
Publicado: (2016)